These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20087897)

  • 1. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
    Karanikolas BD; Figueiredo ML; Wu L
    Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
    Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
    Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
    Karanikolas BD; Figueiredo ML; Wu L
    Mol Cancer Res; 2009 Sep; 7(9):1456-65. PubMed ID: 19723877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer.
    Hoffmann MJ; Engers R; Florl AR; Otte AP; Muller M; Schulz WA
    Cancer Biol Ther; 2007 Sep; 6(9):1403-12. PubMed ID: 18637271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer.
    Saramäki OR; Tammela TL; Martikainen PM; Vessella RL; Visakorpi T
    Genes Chromosomes Cancer; 2006 Jul; 45(7):639-45. PubMed ID: 16575874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 promotes proliferation and invasiveness of prostate cancer cells.
    Bryant RJ; Cross NA; Eaton CL; Hamdy FC; Cunliffe VT
    Prostate; 2007 Apr; 67(5):547-56. PubMed ID: 17252556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
    Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
    Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developmental and androgenic regulation of chromatin regulators EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone methylase complex.
    Duan Z; Zou JX; Yang P; Wang Y; Borowsky AD; Gao AC; Chen HW
    Prostate; 2013 Apr; 73(5):455-66. PubMed ID: 23038103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells.
    Shin YJ; Kim JH
    PLoS One; 2012; 7(1):e30393. PubMed ID: 22272343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repression of E-cadherin by the polycomb group protein EZH2 in cancer.
    Cao Q; Yu J; Dhanasekaran SM; Kim JH; Mani RS; Tomlins SA; Mehra R; Laxman B; Cao X; Yu J; Kleer CG; Varambally S; Chinnaiyan AM
    Oncogene; 2008 Dec; 27(58):7274-84. PubMed ID: 18806826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression analysis of putative stem cell markers in human benign and malignant prostate.
    Ugolkov AV; Eisengart LJ; Luan C; Yang XJ
    Prostate; 2011 Jan; 71(1):18-25. PubMed ID: 20583131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
    Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
    Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
    Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
    J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
    Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
    Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Polycomb Group protein EZH2 regulates actin polymerization in human prostate cancer cells.
    Bryant RJ; Winder SJ; Cross SS; Hamdy FC; Cunliffe VT
    Prostate; 2008 Feb; 68(3):255-63. PubMed ID: 18095286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.
    Bachmann IM; Halvorsen OJ; Collett K; Stefansson IM; Straume O; Haukaas SA; Salvesen HB; Otte AP; Akslen LA
    J Clin Oncol; 2006 Jan; 24(2):268-73. PubMed ID: 16330673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms.
    Koh CM; Iwata T; Zheng Q; Bethel C; Yegnasubramanian S; De Marzo AM
    Oncotarget; 2011 Sep; 2(9):669-83. PubMed ID: 21941025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
    Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
    Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.